Information updates

Anapen® Patient Support

ANAPEN® 150, 300 and 500 adrenaline (epinephrine) autoinjectors are now available in Australia on the PBS as of 1st September 2021 in Australia. 

ANAPEN® is being made available by Allergy Concepts, which has partnered with Arrotex to ensure widespread availability in pharmacies across Australia.  

Email This email address is being protected from spambots. You need JavaScript enabled to view it. to request further information and supply of an ANAPEN® Trainer for demonstrating how to use the device. 

Allergy Concepts has aligned itself with several organisations to offer patient support services, which include:

  • Free ANAPEN® trainers available on demand from treating doctors.
  • ANAPEN® trainers available via Allergy Anaphylaxis Australia (A&AA) and local pharmacies.
  • Free pharmacy support at participating pharmacies that can be located using https://anapen.pharmaprograms.com.au/locator/

The free pharmacy support includes:

  • Device demonstration using an ANAPEN® trainer
  • Patient support pack including an ANAPEN® patient information leaflet, ASCIA Action Plan for Anaphylaxis (ANAPEN® version), ASCIA Travel Plan for Anaphylaxis, ANAPEN® how to use card and access to an optional patient sms/email ANAPEN® expiry reminder.

The Anapen website  www.anapen.com.au includes links to how to use videos, education information, ASCIA and A&AA anaphylaxis resources.

Whilst the availability of another brand of adrenaline autoinjector in Australia should address any future product shortages, it is important that prescribers and their patients are familiar with both brands.

ANAPEN® is available in three dose strengths:

  • 150 microgram for young children (7.5 Kg to 20 Kg )
  • 300 microgram for children (>20 Kg) and adults
  • 500 microgram for anyone weighing more than 50 Kg. 

The range of strengths is included in the 2021 ASCIA Guidelines for Acute Management of Anaphylaxis www.allergy.org.au/hp/papers/acute-management-of-anaphylaxis-guidelines and other ASCIA anaphylaxis resources, such as the ANAPEN® version of the ASCIA Action Plan for Anaphylaxis. To access these resources visit www.allergy.org.au/anaphylaxis   

ASCIA Anaphylaxis e-training courses for Schools, Children’s Education/Care (CEC) and  Community have being updated to include information about ANAPEN® and are available at www.allergy.org.au/about-ascia/about-ascia-e-training

Mod ASCIA Member
Donate to AIFA
go to NAS website
ASCIA Member Login
ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.
See latest edition here...
Join our mailing list:

About ASCIA

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links

About ASCIA

ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Accreditiation

healthdirect

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.